Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer



Status:Recruiting
Healthy:No
Age Range:45 - 74
Updated:12/16/2018
Start Date:July 6, 2017
End Date:August 1, 2030

Use our guide to learn which trials are right for you!

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

This randomized phase III trial studies digital tomosynthesis mammography and digital
mammography in screening patients for breast cancer. Screening for breast cancer with
tomosynthesis mammography may be superior to digital mammography for breast cancer screening
and may help reduce the need for additional imaging or treatment.

PRIMARY OBJECTIVES:

I. To compare the proportions of participants in the tomosynthesis mammography (TM) and
digital mammography (DM) study arms experiencing the occurrence of an ?advanced? breast
cancer at any time during a period of 4.5 years from randomization, including the period of
active screening and a period of clinical follow-up after the last screen (T4).

SECONDARY OBJECTIVES:

I. To assess the potential effect of age, menopausal and hormonal status, breast density, and
family cancer history on the primary endpoint difference between the two arms.

II. To compare the diagnostic performance of TM and DM, as measured by the area under the
receiver operating characteristic (ROC) curve (AUC), sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV).

III. To compare the recall rates and biopsy rates for TM versus DM, with subset analyses by
the same variables as listed in aim II.

IV. To compare the rate of interval cancers for TM and DM and to assess the mechanism of
diagnosis for these interval cancers with categorization by symptomatic versus (vs)
asymptomatic, and how detected: diagnosed via physical examination, mammography, ultrasound
(US), magnetic resonance imaging (MRI) or other technologies.

V. To examine the correlation between Breast Imaging Reporting and Data System (BIRADS)
imaging features and histologic and genetic features, such as invasive ductal and invasive
lobular histology, high grade, high stage at diagnosis, and aggressive genetic subtypes.

VI. To assess different combinations of TM and synthesized 2 dimensional (2D) or DM in reader
studies to assist in determining the optimum balance between diagnostic performance,
radiation exposure and technique.

VII. To estimate and compare breast-cancer-specific mortality between the two study arms.

VIII. To estimate and compare the prevalence of breast cancer subtypes (luminal A, luminal B,
HER2+, basal-like) low, medium or high proliferation via PAM50 proliferation signatures, and
p53 mutant-like or wild-type-like according to a validated p53 dependent signature in the two
arms, overall and stratified on whether cancers were detected through screening or as
interval cancers, and whether cancers were invasive or in situ.

IX. To classify histologically malignant (true positive cases) and benign lesions (false
positive cases) as normal-like or tumor-like using the PAM50 gene expression assay subtype
(luminal A, luminal B, HER2, basal-like,), and low, medium, or high proliferation according
to PAM50 proliferation signatures, and p53 mutant-like or wild-type-like according to a
validated p53-dependent signature.

X. To assess the agreement between local and expert study pathologists for all breast lesions
(benign and malignant) biopsied during the 4.5 years of screening with TM or DM.

XI. To create a blood and buccal cell biobank for future biomarker and genetic testing.

XII. To compare health care utilization (including cancer care received) and cost of an
episode of breast cancer screening by TM versus DM, overall and within subsets.

XIII. To implement a centralized quality control (QC) monitoring program for both 2D digital
mammography (DM) and tomosynthesis (TM), which provides rapid feedback on image quality,
using quantitative tools, taking advantage of the automated analysis of digital images.

XIV. To assess temporal and site-to site variations in image quality, breast radiation dose,
and other quality control parameters in TM vs. DM.

XV. To refine and implement task-based measures of image quality to assess the effects of
technical parameters, including machine type, and detector spatial and contrast resolution on
measures of diagnostic accuracy for TM.

XVI. To evaluate which QC tests are useful for determination of image quality and those that
are predictive of device failure, in order to recommend an optimal QC program for TM.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients undergo bilateral screening DM with standard craniocaudal (CC) and
mediolateral oblique (MLO) views at baseline, 12, 24, 36, and 48 months if pre-menopausal or
at baseline, 24, and 48 months if post-menopausal.

ARM B: Patients undergo manufacturer-defined screening TM at baseline, 12, 24, 36, and 48
months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.

After completion of study, patients are followed up for at least 4.5-8 years after study
entry.

Inclusion Criteria:

- Women of childbearing potential must not be known to be pregnant or lactating

- Patients must be scheduled for, or have intent to schedule, a screening mammogram

- Patients must be able to tolerate digital breast tomosynthesis and full-field digital
mammographic imaging required by protocol, to be performed at an American College of
Radiology Imaging Network (ACRIN)-qualified facility

- Patients must be willing and able to provide a written informed consent

- Patients must not have symptoms or signs of benign or malignant breast disease (eg,
nipple discharge, breast lump) warranting a diagnostic rather than a screening
mammogram, and/or other imaging studies (eg, sonogram); patients with breast pain are
eligible as long as other criteria are met

- Patients must not have had a screening mammogram within the last 11 months prior to
date of randomization

- Patients must not have previous personal history of breast cancer including ductal
carcinoma in situ

- Patients must not have breast enhancements (e.g., implants or injections)

- ANNUAL SCREENING REGIMEN ELIGIBILITY CHECK

- To be eligible for inclusion in the annual screening regimen one of the following
three conditions must be met in addition to the eligibility criteria above:

- Patients are pre-menopausal; OR

- Post-menopausal aged 45-69 with any of the following three risks factors:

- Dense breasts (BIRADS density categories c-heterogeneously dense or
d-extremely dense), or

- Family history of breast cancer (first degree relative with breast cancer),
or, positive genetic testing for any deleterious genes that indicate an
increased risk for breast cancer, or

- Currently on hormone therapy; OR

- Post-menopausal ages 70-74 with either of the following two risk factors:

- Dense breasts (BIRADS density categories c-heterogeneously dense or
d-extremely dense), or

- Currently on hormone therapy

- Postmenopausal women are defined as those with their last menstrual period more than
12 months prior to study entry; for the purpose of defining menopausal status for
women who have had surgical cessation of their periods, women who no longer have
menses due to hysterectomy and oophorectomy will be considered postmenopausal; women
who no longer have menses due to hysterectomy without oophorectomy will be considered
premenopausal until age 52 and postmenopausal thereafter

- All other postmenopausal women are eligible for inclusion in the biennial screening
regimen

- For those women who cannot be assigned to annual or biennial screening at the time of
study entry and randomization because they are postmenopausal, have no family history
or known deleterious breast cancer mutation, are not on hormone therapy AND have not
had a prior mammogram, breast density will be determined by the radiologist?s
recording of it at the time of interpretation of the first study screening
examination, either DM or TM; for those who are randomized to TM, radiologists will
assign BI-RADS density through review of the DM or synthetic DM portion of the TM
examination; such women cannot be part of the planned stratification by screening
frequency and are expected to represent far less than 1% of the Tomosynthesis
Mammographic Imaging Screening Trial (TMIST) population

- Breast density will be determined by prior mammography reports, when available; all
other risk factors used to determine patient eligibility for annual or biennial
screening will be determined by subject self-report
We found this trial at
63
sites
Vancouver, British Columbia
Principal Investigator: Paula B. Gordon
Phone: 888-939-3333
?
mi
from
Vancouver,
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Jennifer A. Harvey
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Stephanie Patterson
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Appleton, Wisconsin 54911
Principal Investigator: Susan Sung
Phone: 844-510-3600
?
mi
from
Appleton, WI
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Lynn D. Baxter
Phone: 404-303-3355
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Dulcy E. Wolverton
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Bakersfield, California 93306
Principal Investigator: David P. Schale
Phone: 661-326-9600
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: James F. Ruiz
Phone: 225-215-1353
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Baton Rouge, Louisiana 70815
Principal Investigator: James F. Ruiz
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Braselton, Georgia 30517
Principal Investigator: Charles H. Nash
Phone: 770-219-8800
?
mi
from
Braselton, GA
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Joseph A. Sparano
Phone: 718-379-6866
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
2600 Sixth St. SW
Canton, Ohio 44710
330.363.4908
Principal Investigator: Shruti Trehan
Phone: 330-363-6891
Aultman Health Foundation The Aultman Foundation will raise and administer funds in order to support...
?
mi
from
Canton, OH
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Carson City, NV
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Cherie Kuzmiak
Phone: 877-668-0683
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
1969 W Ogden Ave
Chicago, Illinois 60612
(312) 864-6000
Principal Investigator: Thomas E. Lad
Phone: 312-864-5204
John H. Stroger, Jr. Hospital of Cook County The Level 1 Trauma Center is one...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Lawrence D. Sobel
Phone: 513-558-4553
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Jeffrey R. Hawley
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: W. P. Evans
Phone: 214-648-7097
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
?
mi
from
Decatur, IL
Click here to add this to my saved trials
3773 Chry Crk North Dr # 101
Denver, Colorado 80209
Principal Investigator: Keren Sturtz
?
mi
from
Denver, CO
Click here to add this to my saved trials
1111 6th Ave
Des Moines, Iowa 50314
(515) 247-3121
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Mercy Medical Center - Des Moines Mercy Medical Center
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
?
mi
from
Duluth, MN
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Lars J. Grimm
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Easton, Pennsylvania 18042
Principal Investigator: Rajen P. Oza
Phone: 610-250-4000
?
mi
from
Easton, PA
Click here to add this to my saved trials
Elmira, New York 14905
Principal Investigator: Chi K. Tsang
Phone: 607-271-7000
?
mi
from
Elmira, NY
Click here to add this to my saved trials
Englewood, Colorado 80112
Principal Investigator: Lora D. Barke
Phone: 303-761-9190
?
mi
from
Englewood, CO
Click here to add this to my saved trials
1301 Punchbowl St
Honolulu, Hawaii 96813
(808) 538-9011
Principal Investigator: Erin Capps
Phone: 888-823-5923
Queen's Medical Center The Queen's Medical Center, located in downtown Honolulu, Hawaii, is a private,...
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
535 Barnhill Dr
Indianapolis, Indiana 46202
(888) 600-4822
Principal Investigator: Steven M. Westphal
Phone: 317-278-5632
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
9548 Park Meadows Drive
Lone Tree, Colorado 80124
Principal Investigator: Dulcy E. Wolverton
?
mi
from
Lone Tree, CO
Click here to add this to my saved trials
600 Highland Ave
Madison, Wisconsin 53792
(608) 263-6400
Principal Investigator: Mai A. Elezaby
Phone: 800-622-8922
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
?
mi
from
Madison, WI
Click here to add this to my saved trials
Marshfield, Wisconsin 54449
Principal Investigator: Adedayo A. Onitilo
Phone: 800-782-8581
?
mi
from
Marshfield, WI
Click here to add this to my saved trials
Memphis, Tennessee 38120
Principal Investigator: Evelyn W. Gayden
Phone: 901-226-3077
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Memphis, Tennessee 38120
Principal Investigator: Evelyn W. Gayden
Phone: 901-226-1366
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Minneapolis, Minnesota 55414
Principal Investigator: David M. King
Phone: 952-993-1517
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
1600 Midtown Avenue
Mount Pleasant, South Carolina 29464
Principal Investigator: Dag Pavic
Phone: 843-792-9321
?
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Mukwonago, Wisconsin 53149
Principal Investigator: Timothy R. Wassenaar
Phone: 888-823-5923
?
mi
from
Mukwonago, WI
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Reagan Leverett
Phone: 800-811-8480
?
mi
from
Nashville, TN
Click here to add this to my saved trials
254 Easton Ave
New Brunswick, New Jersey 08901
(732) 745-8600
Principal Investigator: Susan A. McManus
Phone: 888-823-5923
Saint Peter's University Hospital Located in New Brunswick, NJ, Saint Peter's University Hospital has been...
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Principal Investigator: Mignonne Morrell
Phone: 504-903-3000
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Ralph T. Wynn
Phone: 212-305-6361
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Victoria L. Mango
Phone: 212-639-7592
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
445 E 69th St
New York, New York 10021
(212) 746-1067
Principal Investigator: Michele B. Drotman
Phone: 212-746-1848
Weill Medical College of Cornell University Founded in 1898, and affiliated with what is now...
?
mi
from
New York, NY
Click here to add this to my saved trials
Newark, Delaware 19713
Principal Investigator: Gregory A. Masters
Phone: 302-623-4450
?
mi
from
Newark, DE
Click here to add this to my saved trials
600 Gresham Dr
Norfolk, Virginia 23507
(757) 388-3000
Principal Investigator: John K. Plemmons
Phone: 757-388-2406
Sentara Norfolk General Hospital Sentara Norfolk General Hospital is recognized as the number one ranked...
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Norfolk, Virginia 23502
Principal Investigator: John K. Plemmons
Phone: 757-388-5109
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Oconomowoc, Wisconsin 53066
Principal Investigator: Timothy R. Wassenaar
Phone: 262-928-7878
?
mi
from
Oconomowoc, WI
Click here to add this to my saved trials
320 E North Ave
Pittsburgh, Pennsylvania 15212
(412) 359-3131
Principal Investigator: Betty Shindel
Phone: 877-284-2000
Allegheny General Hospital At Allegheny General Hospital, our physicians and healthcare staff have earned an...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Red Bank, New Jersey 07701
Principal Investigator: Bokran Won
Phone: 732-530-2382
?
mi
from
Red Bank, NJ
Click here to add this to my saved trials
Savannah, Georgia 31405
Principal Investigator: Howard A. Zaren
?
mi
from
Savannah, GA
Click here to add this to my saved trials
Scottsdale, Arizona 85251
Principal Investigator: Denise H. Reddy
Phone: 480-425-4170
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Shreveport, Louisiana 71103
Principal Investigator: Jerry McLarty
Phone: 318-813-1412
?
mi
from
Shreveport, LA
Click here to add this to my saved trials
Spartanburg, South Carolina 29303
Principal Investigator: Amarinthia (Amy) Curtis
Phone: 864-560-6104
?
mi
from
Spartanburg, SC
Click here to add this to my saved trials
602 W University Ave
Urbana, Illinois 61801
(217) 383-3010
Principal Investigator: Kendrith M. Rowland
Phone: 800-446-5532
Carle Cancer Center Carle Cancer Center delivers comprehensive care through leading-edge technology and advanced research,...
?
mi
from
Urbana, IL
Click here to add this to my saved trials
Waukesha, Wisconsin 53188
Principal Investigator: Timothy R. Wassenaar
Phone: 262-928-5539
?
mi
from
Waukesha, WI
Click here to add this to my saved trials
Wexford, Pennsylvania 15090
Principal Investigator: Betty Shindel
Phone: 412-359-3043
?
mi
from
Wexford, PA
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
336-716-2011
Principal Investigator: Kelly Brozzetti Cronin
Phone: 336-713-6771
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
55 N Lake Ave
Worcester, Massachusetts 01655
(508) 856-8989
Principal Investigator: Gopal Vijayaraghavan
Phone: 508-856-3216
Univ of Massachusetts Med School As the commonwealth's only public medical school, we take seriously...
?
mi
from
Worcester, MA
Click here to add this to my saved trials